文献速递产科

择期剖宫产辅助阿奇霉素预防:一项回顾性队列研究

Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth.
PubMed 文献 · Obstet Gynecol · 2023-01-04

该回顾性队列研究在单一三级中心纳入2867例孕周超过23周的单胎择期剖宫产患者,比较实施500 mg静脉阿奇霉素辅助预防前后产后感染复合结局。实施后复合感染发生率3.3% vs 4.8%(aOR 0.60,95%CI 0.40-0.89),伤口感染及伤口浆液肿、裂开风险降低,新生儿结局无差异。

要点

  • 实施辅助阿奇霉素后,剖宫产术后感染复合结局从4.8%降至3.3%(aOR 0.60,95%CI 0.40-0.89)。
  • 伤口感染从3.5%降至2.4%(aOR 0.61,95%CI 0.39-0.98)。
  • 伤口浆液肿和裂开风险降低,新生儿结局无差异。

核心结论

  • 在择期剖宫产中采用辅助阿奇霉素与产后感染 odds 降低相关。

研究设计与样本

  • 回顾性队列研究,纳入单一三级中心孕周超过23周的单胎择期剖宫产患者。
  • 实施前组(pre-AZI组)为2013年1月至2015年9月,实施后组(post-AZI组)为2016年1月至2018年12月。
  • 2015年10月至12月的剖宫产作为洗脱期被排除。
  • 共纳入2867例,pre-AZI组1391例(48.5%),post-AZI组1476例(51.5%);采用多因素分析计算aOR和95%CI,并进行倾向性评分匹配。

主要发现

  • 主要复合感染结局(子宫内膜炎、浅表或深部伤口感染、腹腔脓肿、尿路感染)post-AZI组3.3% vs pre-AZI组4.8%(aOR 0.60,95%CI 0.40-0.89)。
  • 伤口感染post-AZI组2.4% vs pre-AZI组3.5%(aOR 0.61,95%CI 0.39-0.98)。
  • 伤口浆液肿post-AZI组0.5% vs pre-AZI组0.9%(aOR 0.34,95%CI 0.13-0.90)。
  • 伤口裂开post-AZI组0.5% vs pre-AZI组1.2%(aOR 0.32,95%CI 0.13-0.79)。
  • 倾向性评分匹配的1138对中,主要结局post-AZI组仍显著更低(aOR 0.64,95%CI 0.41-0.99)。

关键数值与推荐

  • 干预为在标准术前头孢菌素预防基础上加用500 mg静脉阿奇霉素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate maternal postoperative infections before and after addition of adjunctive azithromycin to standard antibiotic prophylaxis for prelabor cesarean births. METHODS: We conducted a retrospective cohort study of patients with singleton gestations at more than 23 weeks of gestation who underwent prelabor cesarean birth at a single tertiary care center. Deliveries were categorized as those before implementation of 500 mg intravenous azithromycin in addition to standard preoperative cephalosporin antibiotic prophylaxis (pre-AZI group; January 2013-September 2015) and those after implementation of adjunctive azithromycin (post-AZI group; January 2016-December 2018). Cesarean births from October to December 2015 were excluded as a washout period. The primary outcome was a composite of postcesarean infections (endometritis, superficial or deep wound infections, intra-abdominal abscess, urinary tract infections). Secondary outcomes included composite components, other wound or postoperative complications, and select neonatal morbidities. Outcomes were compared between groups, and adjusted odds ratios (aORs) and 95% CIs were calculated using multivariable analysis. Propensity score matching was performed to assess the robustness our analysis. RESULTS: Of 2,867 delivering patients included for analysis, 1,391 (48.5%) were in the pre-AZI group and 1,476 (51.5%) were in the post-AZI group. Patients in the post-AZI group were older and were more likely to have private insurance, use aspirin, and receive predelivery antibiotics within 2 weeks. There were significantly lower odds of composite infection after azithromycin implementation (3.3% vs 4.8%, aOR 0.60, 95% CI 0.40-0.89), driven by a reduction in wound infection odds (2.4% vs 3.5%, aOR 0.61, 95% CI 0.39-0.98). There were lower odds of other postpartum complications, including wound seroma (0.5% vs 0.9%, aOR 0.34, 95% CI 0.13-0.90) and dehiscence (0.5% vs 1.2%, aOR 0.32, 95% CI 0.13-0.79). There were no differences in select neonatal morbidities between groups. Of 1,138 matching sets in the propensity analysis, the primary outcome remained significantly lower in the post-AZI group (aOR 0.64, 95% CI 0.41-0.99). CONCLUSION: Adopting adjunctive azithromycin for prelabor cesarean deliveries was associated with lower odds of postpartum infection.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ruzic MF, Blanchard CT, Cozzi GD, et al. Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth. Obstet Gynecol. 2023. PMID: 36649335. doi:10.1097/AOG.0000000000005037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。